- Home
- LNTH vs HALO Comparison
LNTH vs HALO Comparison
Compare LNTH & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNTH
- HALO
- Stock Information
- Founded
- LNTH 1956
- HALO 1998
- Country
- LNTH United States
- HALO United States
- Employees
- LNTH N/A
- HALO N/A
- Industry
- LNTH Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LNTH Health Care
- HALO Health Care
- Exchange
- LNTH Nasdaq
- HALO Nasdaq
- Market Cap
- LNTH 7.5B
- HALO 7.4B
- IPO Year
- LNTH 2015
- HALO N/A
- Fundamental
- Price
- LNTH $80.10
- HALO $49.48
- Analyst Decision
- LNTH Strong Buy
- HALO Buy
- Analyst Count
- LNTH 5
- HALO 9
- Target Price
- LNTH $133.80
- HALO $63.78
- AVG Volume (30 Days)
- LNTH 1.2M
- HALO 2.1M
- Earning Date
- LNTH 05-07-2025
- HALO 05-06-2025
- Dividend Yield
- LNTH N/A
- HALO N/A
- EPS Growth
- LNTH N/A
- HALO 55.40
- EPS
- LNTH 3.53
- HALO 3.76
- Revenue
- LNTH $1,536,699,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- LNTH $5.81
- HALO $20.06
- Revenue Next Year
- LNTH $12.26
- HALO $24.20
- P/E Ratio
- LNTH $22.52
- HALO $17.71
- Revenue Growth
- LNTH 12.53
- HALO 25.64
- 52 Week Low
- LNTH $74.34
- HALO $41.28
- 52 Week High
- LNTH $126.89
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- LNTH 29.71
- HALO 36.86
- Support Level
- LNTH $78.61
- HALO $58.38
- Resistance Level
- LNTH $83.60
- HALO $69.94
- Average True Range (ATR)
- LNTH 3.81
- HALO 3.06
- MACD
- LNTH -3.05
- HALO -0.11
- Stochastic Oscillator
- LNTH 5.51
- HALO 6.60
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.